Finnish biotech NADMED has awarded the Cleveland Clinic a $30,000 grant to support groundbreaking research led by Dr. Keyue Sun and the Schlegel Lab, focusing on the metabolic assessment of organ viability during transplantation. This project aims to address a critical challenge in transplant medicine: determining whether a donated organ retains sufficient metabolic function after ischemic stress, a period when blood supply is compromised. The research is poised to enhance clinical decision-making in a field where the viability of organs is often uncertain, directly impacting patient outcomes.

The significance of this work lies in its exploration of NAD and NADH dynamics, which are crucial for cellular energy management and mitochondrial function. By investigating how different machine perfusion strategies affect organ metabolism during preservation, the team seeks to identify not just damage but the organ’s overall metabolic resilience. This approach aligns with the broader themes in longevity science, where understanding mitochondrial health is essential for both transplant success and the aging process. The project stands out for its robust scientific foundation and translational potential, promising to refine the criteria for organ viability assessments that can save lives.

The implications of this research extend beyond transplantation, signaling a shift in how we approach biological function in clinical settings. By moving from static assessments to dynamic evaluations of cellular health, this work could pave the way for integrating longevity science into everyday medical practice. As Professor Andrea Schlegel noted, this collaboration with NADMED enhances our mechanistic understanding of mitochondrial injury, ultimately fostering a future where diagnostics based on cellular energy and resilience become standard in clinical decision-making. This award marks a significant step toward making longevity science a practical tool in patient care.

Source: longevity.technology